Cytek® Biosciences Opens New Facility to Address Increasing Global Demand for Cutting-Edge Cell Analysis Solutions
Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, announced today that it has opened a new 50,000-square-foot facility in Wuxi, China. This strategic move increases the company’s manufacturing capacity to meet the growing worldwide demand for comprehensive cell…
Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of Cancer
Numab Therapeutics AG (“Numab”) and Ono Pharmaceutical Co., Ltd. (“Ono”) today announced a global research, development and commercialization collaboration for NM49, a multi-specific antibody designed to activate tumor associated macrophage phagocytosis for the treatment of cancers and identified through Numab’s proprietary…
ABL Bio Taps into Synaffix ADC Technology to Accelerate Development of Bispecific ADC Products
Synaffix B.V., a Lonza company (SIX: LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces a licensing agreement to develop bispecific ADCs with ABL Bio, Inc. (KOSDAQ: 298380),…
